389 related articles for article (PubMed ID: 19147568)
41. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
42. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
[TBL] [Abstract][Full Text] [Related]
43. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
Delehouzé C; Godl K; Loaëc N; Bruyère C; Desban N; Oumata N; Galons H; Roumeliotis TI; Giannopoulou EG; Grenet J; Twitchell D; Lahti J; Mouchet N; Galibert MD; Garbis SD; Meijer L
Oncogene; 2014 Dec; 33(50):5675-87. PubMed ID: 24317512
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.
Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Di Giacomo S; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M
Sci Transl Med; 2019 Jan; 11(477):. PubMed ID: 30700572
[TBL] [Abstract][Full Text] [Related]
45. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells.
Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M
BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222
[TBL] [Abstract][Full Text] [Related]
47. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
48. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
49. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Slack A; Lozano G; Shohet JM
Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
[TBL] [Abstract][Full Text] [Related]
50. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
[TBL] [Abstract][Full Text] [Related]
51. The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme.
Urban-Wójciuk Z; Graham A; Barker K; Kwok C; Sbirkov Y; Howell L; Campbell J; Woster PM; Poon E; Petrie K; Chesler L
Cancer Gene Ther; 2022 Jul; 29(7):940-950. PubMed ID: 34522028
[TBL] [Abstract][Full Text] [Related]
52. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
[TBL] [Abstract][Full Text] [Related]
53. High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
Giannini G; Cerignoli F; Mellone M; Massimi I; Ambrosi C; Rinaldi C; Dominici C; Frati L; Screpanti I; Gulino A
Cancer Res; 2005 Sep; 65(18):8308-16. PubMed ID: 16166307
[TBL] [Abstract][Full Text] [Related]
54. Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.
Schultz CR; Gruhlke MCH; Slusarenko AJ; Bachmann AS
J Nat Prod; 2020 Aug; 83(8):2518-2527. PubMed ID: 32786875
[TBL] [Abstract][Full Text] [Related]
55. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
56. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
[TBL] [Abstract][Full Text] [Related]
57. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.
Henriksen JR; Haug BH; Buechner J; Tømte E; Løkke C; Flaegstad T; Einvik C
BMC Dev Biol; 2011 Jan; 11():1. PubMed ID: 21194500
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice.
Lan L; Trempus C; Gilmour SK
Cancer Res; 2000 Oct; 60(20):5696-703. PubMed ID: 11059762
[TBL] [Abstract][Full Text] [Related]
59. Induction of ornithine decarboxylase activity is a necessary step for mitogen-activated protein kinase kinase-induced skin tumorigenesis.
Feith DJ; Bol DK; Carboni JM; Lynch MJ; Sass-Kuhn S; Shoop PL; Shantz LM
Cancer Res; 2005 Jan; 65(2):572-8. PubMed ID: 15695401
[TBL] [Abstract][Full Text] [Related]
60. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
